UHPLC/MS Analysis of Antineoplastic and Antidepressant Drugs in Plasma on Titan™ C18 after SPE using HybridSPE®-PLus

HybridSPE-Phospholipid plates removed plasma-derived proteins and phospholipids to maximize LC/MS sensitivity. Titan C18 U/HPLC columns provided rapid resolution. Fluka LC-MS Ultra CHROMASOLV solvents were used to supply low background interference and low particulate contaminants for robust, trouble-free operation. Cerilliant CRMs provided reliable identification and quantification.

market focus	Pharmaceutical (small molecule)
sample/matrix	rat plasma
SPE well plate	HybridSPE-PLus 96-Well Plate, 50 mg/2 mL per well (575659-U)
sample addition	400 µL of 1% formic acid acetonitile:spiked plasma (3:1) per well
sample preparation	final analyte concentration 50 ng/mL
column	Titan C18, 5 cm x 2.1 mm I.D., 1.9 µm particles (577122-U)
mobile phase	[A] 5 mM ammonium formate; [B] 5 mM ammonium formate in 90:10 (v:v) acetonitrile:water
gradient	35 to 90% B in 1.5 min, held at 90% B for 0.4 min
flow rate	0.4 mL/min
pressure	3582 psi (247 bar)
column temp.	35 °C
detector	TOF/MS
injection	1 µL
Application No.	G006151



Related Products

analytical column
Titan™ C18 UHPLC Column, 1.9 micron (Supelco 577122-U)
mobile phase component
Acetonitrile (Sigma-Aldrich 34851)
Ammonium formate (Fluka 14266)
Water (Fluka 14263)
SPE tube or plate
HybridSPE®-PLus 96-Well Plate (Supelco 575659-U)
standard
Fluoxetine hydrochloride solution (Cerilliant F-918)
Tamoxifen (Sigma T5648)